An Expanded Access Program for AM0010 (Pegilodecakin)

Summary

This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications